Results from Edwards Lifesciences Corp.'s PARTNER 2 transcatheter aortic valve replacement (TAVR) study will be presented at a late-breaking clinical trial session at the annual American College of Cardiology conference in Chicago in early April.
PARTNER 2, which evaluates Edwards’ Sapien XT and Sapien 3 TAVR systems, will likely attract significant attention at the gathering. One section of the trial compared Sapien XT to surgery...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?